版本:
中国

BRIEF-Fortress Biotech announces final patient dosed in phase 1B trial of cael-101

May 4 Fortress Biotech Inc:

* Fortress Biotech announces final patient dosed in phase 1b trial of cael-101 for the treatment of al amyloidosis

* Expects to readout preliminary phase 1B data mid-2017, and full data by end of year Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐